Linsitinib (OSI-906)

製品コードS1091

Linsitinib (OSI-906)化学構造

分子量(MW):421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

サイズ 価格(税別)  
JPY 31540.00
JPY 28220.00
JPY 44820.00
JPY 119520.00

カスタマーフィードバック(4)

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

製品安全説明書

IGF-1R阻害剤の選択性比較

生物活性

製品説明 Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
ターゲット
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外試験

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LsZ2lEPTB;MD6wNlgxPiEQvF2= NV\1XZN4W0GQR1XS
KS-1 NIfTS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnsTWM2OD1yLkCzPFM2KM7:TR?= NHi4[I1USU6JRWK=
TE-11 M3vBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1niRmlEPTB;MD6wO|gzOiEQvF2= MoXEV2FPT0WU
EW-1 NX;zU2dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jF[WlEPTB;MD6wPFU5PSEQvF2= NYjKe4ZlW0GQR1XS
HMV-II NVn2XpNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHzW2hKSzVyPUCuNFg5PDZizszN NUTicnBCW0GQR1XS
COLO-205 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMUC0OVQh|ryP NYeweZlWW0GQR1XS
ES1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfyTm9qUUN3ME2wMlExPjl4IN88US=> MXPTRW5ITVJ?
GDM-1 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLNOoRKSzVyPUCuNVM3PzJizszN M{DoR3NCVkeHUh?=
ML-2 NEjY[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj2TJJ6UUN3ME2wMlE2QDl4IN88US=> NEGwdVlUSU6JRWK=
Saos-2 Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf3fmxKSzVyPUCuNVY2OjZizszN NV3KVnlGW0GQR1XS
NCI-H1355 M3LRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nSV2lEPTB;MD6xPFE{PSEQvF2= NYTMZpBWW0GQR1XS
G-401 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP4OnZTUUN3ME2wMlE5OjNizszN M3K1TnNCVkeHUh?=
EW-16 MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17rSWlEPTB;MD6xPFc4PyEQvF2= NV\aRYtPW0GQR1XS
EW-7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPnTWM2OD1yLkG4PFgyKM7:TR?= MlHMV2FPT0WU
NCI-H727 NX3rR25vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DGXGlEPTB;MD6xPVc6PCEQvF2= NHPIcm9USU6JRWK=
LCLC-97TM1 NYrycZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInrXpZKSzVyPUCuNlA6PTVizszN MoPxV2FPT0WU
NCI-H650 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfjTWM2OD1yLkKxN|g1KM7:TR?= M1ztVXNCVkeHUh?=
NCI-H2122 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMkOyPVkh|ryP MYDTRW5ITVJ?
SK-N-DZ NX3Ucng1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMkO2PVgh|ryP MoPhV2FPT0WU
HT-29 M4\CcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;CWG9KSzVyPUCuNlQzPDhizszN NUD2Z3JxW0GQR1XS
LB771-HNC NIjLfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HIZWlEPTB;MD6yOVkyPSEQvF2= MXnTRW5ITVJ?
HT-144 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLaTWM2OD1yLkK2NVkyKM7:TR?= M1;mUnNCVkeHUh?=
LAN-6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMk[zOFgh|ryP M37qSXNCVkeHUh?=
EW-18 MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMkewNFEh|ryP NH2yNo5USU6JRWK=
LS-1034 M1XJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PrfmlEPTB;MD6yO|E{OiEQvF2= MYjTRW5ITVJ?
EW-11 NILUZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnjPVZWUUN3ME2wMlI5PDN{IN88US=> NGTjbFJUSU6JRWK=
SNU-C1 M33aUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFThUIRKSzVyPUCuNlk{OTNizszN M4DoTnNCVkeHUh?=
RS4-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f5OGlEPTB;MD6zN|c2QCEQvF2= MmDVV2FPT0WU
ES4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwNEGwN|gh|ryP M3f3enNCVkeHUh?=
COLO-320-HSR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfrTWM2OD1yLkSxN|Y5KM7:TR?= MmXyV2FPT0WU
NB10 M37jZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwNEW0N|ch|ryP MlPoV2FPT0WU
BFTC-905 NVT6U4g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwNE[3OVgh|ryP NUDlfnJOW0GQR1XS
A375 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwNEe2NVch|ryP NXfE[WpwW0GQR1XS
SJRH30 NFfVe2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXRTWM2OD1yLkWwPFIzKM7:TR?= MVzTRW5ITVJ?
NOS-1 NX7NW21GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\VSGlEPTB;MD61NlI3PyEQvF2= M2\WS3NCVkeHUh?=
SIG-M5 NVLVPYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwNUO1OVch|ryP NHrZVIFUSU6JRWK=
DOK NWjic5FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD4[|d1UUN3ME2wMlU2PiEQvF2= Mo\wV2FPT0WU
NB69 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfmRpRKSzVyPUCuOVgzPTdizszN M4rhNHNCVkeHUh?=
SK-NEP-1 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vQUWlEPTB;MD62NFI{PiEQvF2= M4nMcHNCVkeHUh?=
SK-MM-2 NHPTVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfwTWM2OD1yLk[1OFkyKM7:TR?= M4jUTnNCVkeHUh?=
NCI-H358 M{nT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;PWmtKSzVyPUCuOlcxQDJizszN MmO0V2FPT0WU
RH-1 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHLWFd2UUN3ME2wMlc1QDV7IN88US=> MoLGV2FPT0WU
NH-12 M2DQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwN{[wOFYh|ryP NUTMRYpZW0GQR1XS
TE-12 NYDYN5RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;wTWM2OD1yLke2OFg3KM7:TR?= Mnm0V2FPT0WU
COLO-668 M2PWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XBTmlEPTB;MD64OFY3PiEQvF2= M1u4NnNCVkeHUh?=
PANC-08-13 NHzmNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jYTGlEPTB;MD64OlM4PyEQvF2= NHfVXm5USU6JRWK=
HCC2998 M1jxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HvOWlEPTB;MD64PFI3OyEQvF2= NETuTGtUSU6JRWK=
ABC-1 NV\oRoNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwOUCzOVIh|ryP NXPhRotPW0GQR1XS
ES6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrSSI5KSzVyPUCuPVExPjZizszN MV3TRW5ITVJ?
SNU-387 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3iTWM2OD1yLkm5N|k{KM7:TR?= MnPpV2FPT0WU
CMK M4fKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH2RXZiUUN3ME2wMlk6QTJ7IN88US=> MkjBV2FPT0WU
SJSA-1 NXHGcWttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXUTWM2OD1zLkCzOlU{KM7:TR?= MWLTRW5ITVJ?
SIMA M1vLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XBPGlEPTB;MT6wOlgzPSEQvF2= NX7aUJJbW0GQR1XS
ES3 NFnTV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\USldKSzVyPUGuNVIzQTdizszN MYfTRW5ITVJ?
IGROV-1 NFHzPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;YUWlEPTB;MT6xOVQ1PCEQvF2= M3O3SXNCVkeHUh?=
MEL-JUSO Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwMUW3OVkh|ryP MXrTRW5ITVJ?
T84 NFH5ZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jPc2lEPTB;MT6yNFkyPCEQvF2= MYrTRW5ITVJ?
CAL-85-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwMkOxN|gh|ryP MX\TRW5ITVJ?
RD MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwMk[0OVUh|ryP NEn2eZpUSU6JRWK=
TE-8 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLQPWVKSzVyPUGuN|E1PjJizszN NXG2bI01W0GQR1XS
L-363 MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\0TWM2OD1zLkO0NlA5KM7:TR?= MYDTRW5ITVJ?
EKVX MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7TTWM2OD1zLkO0OVY5KM7:TR?= MoPoV2FPT0WU
SK-MEL-3 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHWzRYVKSzVyPUGuOFg2PTZizszN MljnV2FPT0WU
TGBC24TKB MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqyeo9KSzVyPUGuOVAyQTNizszN NH;sS2hUSU6JRWK=
NCI-H1770 M1mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTZZpdNUUN3ME2xMlUyOTF|IN88US=> MkS4V2FPT0WU
HuH-7 NXXxdWtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfS[3E4UUN3ME2xMlYxODl6IN88US=> MYDTRW5ITVJ?
HL-60 NGnnZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\WZZhKSzVyPUGuOlY6OjhizszN MUnTRW5ITVJ?
TE-1 NFvsTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fEbGlEPTB;MT63NFk1PSEQvF2= M4PYXHNCVkeHUh?=
LC-2-ad M3HDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwN{O4PFch|ryP NVPHcZVRW0GQR1XS
LB647-SCLC M2m3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETVVIVKSzVyPUGuO|Y2QDNizszN M4jOZ3NCVkeHUh?=
NCI-H2171 MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHQTWM2OD1zLke3O|E3KM7:TR?= MXjTRW5ITVJ?
SK-PN-DW Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlviTWM2OD1zLkmxNlk5KM7:TR?= M2fEWnNCVkeHUh?=
MC-IXC NYLXVWFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXexSpNQUUN3ME2xMlk5QThizszN MXnTRW5ITVJ?
LS-513 NI\XVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTkVXJPUUN3ME2yMlA2OzB3IN88US=> Mkf1V2FPT0WU
EW-3 NWfJW|lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLmNYpKSzVyPUKuNFk5PDRizszN MUfTRW5ITVJ?
OPM-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwMUCyJO69VQ>? NWnHdmNPW0GQR1XS
LP-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3wTWM2OD1{LkK1PFA4KM7:TR?= MYXTRW5ITVJ?
LU-134-A NITYWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnOV2FKSzVyPUKuNlc4KM7:TR?= MV;TRW5ITVJ?
CP66-MEL NGXNc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\idodTUUN3ME2yMlI6ODF2IN88US=> M1j5OHNCVkeHUh?=
HCC1143 M4ftfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTuWIZKSzVyPUKuOFU{PjhizszN MV\TRW5ITVJ?
LOXIMVI M{fue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ni[2lEPTB;Mj62NFIyKM7:TR?= NVnNPWE2W0GQR1XS
TE-10 NUHEcm1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJwN{C4N|gh|ryP Mm\RV2FPT0WU
NCI-H1882 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jEcGlEPTB;Mj63OVIzPyEQvF2= NEPWcZhUSU6JRWK=
CHP-126 NULIeFY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:3TWM2OD1{Lke2N|E4KM7:TR?= M1\aN3NCVkeHUh?=
NCI-H1623 NY\QXHM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;yc2lEPTB;Mj65NlAzPCEQvF2= MVHTRW5ITVJ?
GB-1 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HpXmlEPTB;Mj65N|QxPCEQvF2= NGDHdXVUSU6JRWK=
RCC10RGB Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7vb5NYUUN3ME2yMlk2OjhzIN88US=> NEHBTXlUSU6JRWK=
NCI-H2141 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rNR2lEPTB;Mj65Olg6PiEQvF2= NUTV[GFbW0GQR1XS
GI-ME-N MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTzWWRSUUN3ME2zMlAxPTZ3IN88US=> M2G3bnNCVkeHUh?=
NCI-H526 M2m0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHvTWM2OD1|LkC0NFg2KM7:TR?= M2\XOXNCVkeHUh?=
NCI-H747 M2jGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S2cWlEPTB;Mz6wOFk6OiEQvF2= M3TNZ3NCVkeHUh?=
SNU-423 M1n2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNwMkCzNVMh|ryP MXXTRW5ITVJ?
A427 M4T0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXCWnNKSzVyPUOuNlU3QTlizszN NULSRXltW0GQR1XS
CAL-12T NU\ke3lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7vTWM2OD1|LkSwO|E{KM7:TR?= MWTTRW5ITVJ?
LU-99A MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\INmlEPTB;Mz60O|ExPSEQvF2= MmPnV2FPT0WU
MS-1 NYLDXmFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLJTWM2OD1|LkWzOFI6KM7:TR?= NFLG[ZBUSU6JRWK=
SK-LU-1 M1ewOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNwN{[yPVUh|ryP NFHrPFhUSU6JRWK=
SW837 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTBTWM2OD1|Lke2N|M{KM7:TR?= NWTadm1tW0GQR1XS
ES8 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK3SldVUUN3ME2zMlg{QDd5IN88US=> NIjwdmNUSU6JRWK=
MZ2-MEL NX73ZWc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvYZo5KSzVyPUOuPVIxQDZizszN Mlj5V2FPT0WU
TGW MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHPTWM2OD12LkCxN|EyKM7:TR?= MWXTRW5ITVJ?
GP5d MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DSRWlEPTB;ND6wOVM3OiEQvF2= NVnlUJljW0GQR1XS
BB49-HNC Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPv[o5KSzVyPUSuNVUzOTNizszN MmXOV2FPT0WU
NB13 NVHhZYtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRwMk[4PFch|ryP Ml[yV2FPT0WU
NTERA-S-cl-D1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfiTWM2OD12LkK4OlE2KM7:TR?= NXrRWYs5W0GQR1XS
NCI-H1648 M33BUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj2TWM2OD12LkK5PFE6KM7:TR?= M1mwdHNCVkeHUh?=
LCLC-103H MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljLTWM2OD12LkOyNVk2KM7:TR?= NUW0coVxW0GQR1XS
LS-411N M3HqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XHXmlEPTB;ND60OFg5PSEQvF2= MVfTRW5ITVJ?
NCI-H1092 NW\oXIs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT2TWM2OD12LkS1Olg4KM7:TR?= NWS5cVNHW0GQR1XS
PANC-10-05 NHj2V|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWntVnJGUUN3ME20MlY6QDRizszN NUjqT2VvW0GQR1XS
DK-MG MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv1VZZ[UUN3ME20MlgxQTN|IN88US=> M3XyNXNCVkeHUh?=
OVCAR-5 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLBNXZPUUN3ME20MlgyOjJ4IN88US=> NYXKR|BnW0GQR1XS
CAL-39 NWX0N4d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jKc2lEPTB;ND64O|Y4KM7:TR?= Mli1V2FPT0WU
TE-441-T NV61OHN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nUZmlEPTB;ND65NFU{PyEQvF2= M3mydnNCVkeHUh?=
MOLT-16 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T0[GlEPTB;ND65OVI2OyEQvF2= NInuSmhUSU6JRWK=
MCF7 NUfocGR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfrUG9FUUN3ME21MlE1PTF5IN88US=> MYHTRW5ITVJ?
CAPAN-1 NVPNd3NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLoTWM2OD13LkK1O|A4KM7:TR?= M3LUW3NCVkeHUh?=
PSN1 NYf4UXFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\LTWM2OD13LkK3NlM2KM7:TR?= NYrMO|VsW0GQR1XS
NCI-H292 M13yRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrmSohmUUN3ME21MlMxODR2IN88US=> MoTmV2FPT0WU
CPC-N MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7jSpdKSzVyPUWuN|k1OTlizszN M3XKOHNCVkeHUh?=
DoTc2-4510 NVrLTWtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz6bnNKSzVyPUWuOFU{PzFizszN MoHOV2FPT0WU
LB1047-RCC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTVwNUW5N|Mh|ryP M2TDdHNCVkeHUh?=
MHH-ES-1 NGCxV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\zN2xUUUN3ME21MlU6QTB5IN88US=> MlH3V2FPT0WU
NMC-G1 NVLzcFZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTVwN{CyNlch|ryP MWjTRW5ITVJ?
SW1710 M2T6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\nZ49KSzVyPUWuO|Q4PTFizszN NYrJdnlXW0GQR1XS
YAPC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj6PVBKSzVyPUWuO|YzODFizszN M2jDT3NCVkeHUh?=
22RV1 NXPQN5o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXiUXRKSzVyPUWuPFAxOTlizszN NGfGOG5USU6JRWK=
COLO-679 M2fEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D5eWlEPTB;NT64PFk1QCEQvF2= M{D4WnNCVkeHUh?=
TCCSUP MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jlXmlEPTB;NT65N|I2QSEQvF2= MkHOV2FPT0WU
C2BBe1 Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC2TG1KSzVyPUWuPVM6PyEQvF2= NXnVSIxZW0GQR1XS
TE-15 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHWTWM2OD14LkC2OlA2KM7:TR?= MWLTRW5ITVJ?
SCLC-21H NFiz[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHHc5VKSzVyPU[uNVA5PDNizszN MULTRW5ITVJ?
EoL-1-cell MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7vTWM2OD14LkG2OVY{KM7:TR?= M{izcXNCVkeHUh?=
NKM-1 NH\MdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuyS5k6UUN3ME22MlE3PzFizszN M{XIfnNCVkeHUh?=
NCI-H1304 NYWwNod1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TXNmlEPTB;Nj6yO|QzQCEQvF2= M3Lsb3NCVkeHUh?=
NB6 NVyxXHNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjqTWM2OD14LkK5OlIzKM7:TR?= NX7LPJB7W0GQR1XS
NALM-6 NX\lWmZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4frb2lEPTB;Nj6zN|I{KM7:TR?= MknZV2FPT0WU
NCI-H522 NXjqU4V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7WWXRKSzVyPU[uN|M{ODZizszN M{\JbHNCVkeHUh?=
MV-4-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnPXVc4UUN3ME22MlM4ODd7IN88US=> NXW4XmJ4W0GQR1XS
LB2241-RCC M{j4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHpTWM2OD14LkO4OlY4KM7:TR?= M3G4THNCVkeHUh?=
NCI-H1417 M1zMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTZwNEC4OFch|ryP NHqzT3lUSU6JRWK=
HT-1197 NFTxN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTZwNUexNlIh|ryP M1HscHNCVkeHUh?=
P30-OHK NVTHUGx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvQeYFlUUN3ME22MlYzPzdizszN MnXFV2FPT0WU
ALL-PO M{C1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrITWM2OD14LkexPVE3KM7:TR?= M1;jeHNCVkeHUh?=
OVCAR-4 NHzQWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTaZ3BKSzVyPU[uO|U1ODVizszN M176UHNCVkeHUh?=
HCC2157 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTZwN{e0O|Uh|ryP MVXTRW5ITVJ?
NCI-H838 NVzZNHd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHraVY9KSzVyPU[uPVY1QSEQvF2= NWWzSXdSW0GQR1XS
NCI-H1299 M3Hab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHWUFJQUUN3ME22Mlk4ODlizszN MUnTRW5ITVJ?
SW954 NGLkOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\tT4VVUUN3ME23MlIxODZ6IN88US=> Mn7UV2FPT0WU
NCI-H441 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\sSGlEPTB;Nz6zOFA3PSEQvF2= MWnTRW5ITVJ?
SK-MEL-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG3TWM2OD15LkS4N|c{KM7:TR?= MkezV2FPT0WU
KARPAS-45 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnjNZlKSzVyPUeuOlU6OjlizszN NVHHRnhlW0GQR1XS
CAL-54 M2j1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTdwOEK5O|ch|ryP NY\S[JhEW0GQR1XS
KYSE-180 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILPTZNKSzVyPUeuPFg6PDFizszN NV\aN5NXW0GQR1XS
NCI-H187 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13FcmlEPTB;Nz65OVk1PyEQvF2= MnfuV2FPT0WU
RT-112 NYnHXFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLkWItrUUN3ME24MlA6Pjd5IN88US=> NW\EZVRuW0GQR1XS
NCI-H1437 NXn1NHlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrYTotKSzVyPUiuNFk4QTVizszN NIrWOYZUSU6JRWK=
SNU-449 NH;BVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;VOGQ{UUN3ME24MlI5Ojd{IN88US=> NFrHcHVUSU6JRWK=
HCC1187 NFfMeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fLdGlEPTB;OD6yPVM6OSEQvF2= MWLTRW5ITVJ?
NCI-H2030 NGDoclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\ETWM2OD16LkO3O|E1KM7:TR?= MYjTRW5ITVJ?
HuO-3N1 NUDIZlB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRThwM{e4OFQh|ryP Ml;QV2FPT0WU
COLO-792 MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17Ie2lEPTB;OD60NVUzPyEQvF2= MmfxV2FPT0WU
MIA-PaCa-2 NEiwUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX5bZVjUUN3ME24Mlg2PTB6IN88US=> NV21VHRxW0GQR1XS
SK-N-FI NX72cGNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTlwMESyOUDPxE1? NHHHNFJUSU6JRWK=
MMAC-SF NX\qeZlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HLR2lEPTB;OT6wPVc2OSEQvF2= Mn:1V2FPT0WU
NCI-H28 NFHNO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn6R4VtUUN3ME25MlExPDZ7IN88US=> NWPVOGtDW0GQR1XS
ETK-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHqVVVKSzVyPUmuNlk6PzRizszN Ml\HV2FPT0WU
NCI-H1993 NFLqc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i2[mlEPTB;OT60OFI3OSEQvF2= M2X0VHNCVkeHUh?=
no-11 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTlwNEexNkDPxE1? MnTQV2FPT0WU
ChaGo-K-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3wZ3hGUUN3ME25MlUyPTh|IN88US=> MXPTRW5ITVJ?
NCCIT NGjPVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHYOoNKSzVyPUmuOVMyPjlizszN MYrTRW5ITVJ?
SAS MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDI[W1kUUN3ME2xNE4zPDhizszN M13WR3NCVkeHUh?=
A673 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFyLkO3NFQh|ryP NFf2OmVUSU6JRWK=
NCI-H1522 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFyLkO3NFch|ryP MVTTRW5ITVJ?
NCI-H810 NYHVRVJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;adXBKSzVyPUGwMlM6ODdizszN M1:1d3NCVkeHUh?=
IST-MES1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFyLkS1OlQh|ryP MWTTRW5ITVJ?
GR-ST MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFyLkWwNlQh|ryP NVe4SWdnW0GQR1XS
SUP-T1 NEPD[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKzc4hKSzVyPUGwMlc{OTdizszN M4DKdnNCVkeHUh?=
NB5 NIHCfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PSbWlEPTB;MUCuPVAzOiEQvF2= M1\NS3NCVkeHUh?=
MZ1-PC NX7Q[|dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TDRWlEPTB;MUCuPVU4OSEQvF2= M3zpUnNCVkeHUh?=
SK-CO-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S5WmlEPTB;MUCuPVk{OSEQvF2= NVyxc5J4W0GQR1XS
Capan-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e3S2lEPTB;MUGuN|E6QCEQvF2= MV3TRW5ITVJ?
697 NXqzNXFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFzLk[3OVch|ryP MVXTRW5ITVJ?
REH Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLLTWM2OD1zMT63OFUyKM7:TR?= NFjLSYVUSU6JRWK=
GI-1 NWPzeIFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e4NGlEPTB;MUGuPFYyPSEQvF2= NFzMVYVUSU6JRWK=
BB65-RCC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW4TWM2OD1zMj6wPVE3KM7:TR?= NV\QZZFJW0GQR1XS
NCI-H1651 NEPj[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXxZlRKSzVyPUGyMlI1PzhizszN NWHjVIJZW0GQR1XS
NCI-H1618 NYroOJU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[wTWM2OD1zMj6zPVc3KM7:TR?= M{PBZ3NCVkeHUh?=
NCI-H2081 NH7ROVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;hU2lEPTB;MUKuOlE1OSEQvF2= NFLZfmJUSU6JRWK=
GCIY NHLqbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PiZWlEPTB;MUKuO|IyOyEQvF2= NHr1RmNUSU6JRWK=
NY MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF|LkC2OFMh|ryP M4jaZXNCVkeHUh?=
PANC-03-27 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16wNGlEPTB;MUOuNFgxPyEQvF2= Ml\BV2FPT0WU
BHY NVfic5UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLpXJY{UUN3ME2xN{4zOTJzIN88US=> NYf5N29bW0GQR1XS
SK-OV-3 M1HLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\qSmI6UUN3ME2xN{4{PzZ|IN88US=> MUnTRW5ITVJ?
5637 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfxR2lpUUN3ME2xN{44PzV7IN88US=> M3Kzb3NCVkeHUh?=
LC-1F Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M176e2lEPTB;MUSuNFM2PiEQvF2= NIHmUI9USU6JRWK=
SNB75 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hyb2lEPTB;MUSuNFM5OyEQvF2= Ml;zV2FPT0WU
CHP-212 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n4O2lEPTB;MUSuNFQ3PCEQvF2= MUDTRW5ITVJ?
HT-1376 NFnEdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHH[XczUUN3ME2xOE4yOTJ4IN88US=> Mn3xV2FPT0WU
MONO-MAC-6 M3f6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TYcmlEPTB;MUSuNVUxOiEQvF2= MYrTRW5ITVJ?
CA46 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF2LkG4Nlch|ryP MXzTRW5ITVJ?
SCC-15 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjDfVRzUUN3ME2xOE42PTh|IN88US=> NV\icY5xW0GQR1XS
ATN-1 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELJ[FNKSzVyPUG0MlY3OjdizszN MlLuV2FPT0WU
NCI-H2405 M3;1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF2LkixOVch|ryP NX2zVVFvW0GQR1XS
NCI-H716 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLKSJBNUUN3ME2xOE45PDl|IN88US=> MX7TRW5ITVJ?
SW620 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jwdWlEPTB;MUSuPVAyPCEQvF2= MkTOV2FPT0WU
NCI-H226 NFrMc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fMNWlEPTB;MUSuPVA5PSEQvF2= NXv4TXNFW0GQR1XS
SW962 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojjTWM2OD1zND65OFMzKM7:TR?= M1e3TnNCVkeHUh?=
KYSE-150 NYTwVpM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK2TWM2OD1zND65OVUh|ryP NHzSWZpUSU6JRWK=
OCUB-M MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETERZZKSzVyPUG0Mlk5QDNizszN MkTKV2FPT0WU
ES7 NGq5bpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj5TWM2OD1zNT6wPVg1KM7:TR?= MnH3V2FPT0WU
SW1463 NEGxdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\qNFVGUUN3ME2xOU41OjJ|IN88US=> NHjhSIJUSU6JRWK=
CAKI-1 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHizenlKSzVyPUG1MlU{PDZizszN MUHTRW5ITVJ?
MKN28 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DsNGlEPTB;MUWuOVQ4QSEQvF2= M2jLZ3NCVkeHUh?=
SW13 NUDj[4gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;j[plKSzVyPUG1MlYyQCEQvF2= M1n4dHNCVkeHUh?=
A3-KAW M4\Cemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3RTWM2OD1zNT65Olk4KM7:TR?= NX:5bmtEW0GQR1XS
LU-65 NE\CV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\iPHpKSzVyPUG1Mlk4PjhizszN NEPocXJUSU6JRWK=
Calu-1 NUSxPHFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjpT5BKSzVyPUG2MlA{PjhizszN M1;qVHNCVkeHUh?=
ST486 M3qzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf0O3FKSzVyPUG2MlA1OzFizszN NWK0bohqW0GQR1XS
BB30-HNC NV3YPZV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPXTWVvUUN3ME2xOk4yOjR4IN88US=> Mm[0V2FPT0WU
EGI-1 M3PVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHwTWM2OD1zNj60OFYh|ryP MX\TRW5ITVJ?
SH-4 NY[2XJFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF4LkS3N|Eh|ryP NXr1SnJXW0GQR1XS
MN-60 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfkN4VlUUN3ME2xO{4zOjl5IN88US=> Mm\tV2FPT0WU
MPP-89 NIXsPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfUdINKSzVyPUG3MlI1PTlizszN NUDDU4lvW0GQR1XS
A2780 NXjVVVJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm0WlRKSzVyPUG3MlQyOzlizszN MWrTRW5ITVJ?
Daoy NFzr[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF5LkS2PVUh|ryP NV7I[|NwW0GQR1XS
NCI-H2126 NVjINVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorZTWM2OD1zNz60O|cyKM7:TR?= MoTqV2FPT0WU
NCI-H1563 NGfkUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF5LkS5NVch|ryP NVzpeVAxW0GQR1XS
8-MG-BA MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;OU2NKSzVyPUG3MlY3PDhizszN M{DXdHNCVkeHUh?=
786-0 M4fneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjkZnBKSzVyPUG3Mlg{PTNizszN NVLMN5pIW0GQR1XS
AM-38 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF5LkmzNFYh|ryP MVPTRW5ITVJ?
COLO-824 NXnwWnRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LqcGlEPTB;MUiuOFQ{PiEQvF2= MlvpV2FPT0WU
SK-MEL-30 NWLFTZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\rSYhKSzVyPUG4MlUxQDJizszN NHHndZFUSU6JRWK=
CESS NVf1[GM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn6c4lKSzVyPUG4Mlc3ODlizszN NXfhXnlUW0GQR1XS
BL-70 NVfVdoRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\BfGlEPTB;MUiuPFE2PiEQvF2= M2n0[XNCVkeHUh?=
NCI-H2170 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO2TWM2OD1zOD65NVc6KM7:TR?= NWPMVWVqW0GQR1XS
HT-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF6Lkm4N{DPxE1? NEW0Z2ZUSU6JRWK=
BOKU NULjOIVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3ZTWM2OD1zOT6wN|gyKM7:TR?= Ml[zV2FPT0WU
HPAF-II NUPUOod4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nSbGlEPTB;MUmuN|AyPSEQvF2= MnTlV2FPT0WU
KGN MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;pR2lEPTB;MUmuOFc3PSEQvF2= NUPiZ5BwW0GQR1XS
MC-CAR NHXUPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXyWY1KSzVyPUG5MlY{OTNizszN MVTTRW5ITVJ?
BHT-101 M3zD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHXXJZKSzVyPUG5Mlc4PyEQvF2= Mo[yV2FPT0WU
SW1783 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTi[41YUUN3ME2xPU44QDB4IN88US=> M1;FW3NCVkeHUh?=
KP-N-YN NVTtbJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e0R2lEPTB;MkCuNFI3OiEQvF2= MVfTRW5ITVJ?
LU-165 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DXZWlEPTB;MkCuOVU4OSEQvF2= NVnBOmo5W0GQR1XS
GOTO NIPKNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH20U5FKSzVyPUKwMlY1PTFizszN Mkj6V2FPT0WU
EFM-19 Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJzLkC3NVYh|ryP M4TFZnNCVkeHUh?=
CTV-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLvTWM2OD1{MT6xNFU1KM7:TR?= MXzTRW5ITVJ?
HEL NVjST4VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\CNmlEPTB;MkGuOFIyPiEQvF2= NULhcWpVW0GQR1XS
SNU-C2B M4DjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGydlE6UUN3ME2yNU41OjZizszN MV\TRW5ITVJ?
ECC4 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO2NW1KSzVyPUKxMlcxPyEQvF2= MmDMV2FPT0WU
NEC8 M2W5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJzLkizOlgh|ryP MmCyV2FPT0WU
KMOE-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnyTWM2OD1{MT64PVIyKM7:TR?= MkCyV2FPT0WU
NCI-H524 NFzmNGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ{LkC4NFgh|ryP NVS5R2s{W0GQR1XS
WSU-NHL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ{LkG1O|ch|ryP MUjTRW5ITVJ?
SF126 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S0bWlEPTB;MkKuNlQ3QSEQvF2= MUTTRW5ITVJ?
HOP-92 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPiOWdmUUN3ME2yNk4{OTZ5IN88US=> MXLTRW5ITVJ?
CTB-1 NHjNZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHt[Ip2UUN3ME2yNk41Pjd5IN88US=> M3rOUnNCVkeHUh?=
KYSE-270 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TONmlEPTB;MkKuPVM2PyEQvF2= MmryV2FPT0WU
SK-MEL-24 NIH3XXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjsSW0zUUN3ME2yN{4yQDdizszN NFzqeFFUSU6JRWK=
Calu-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfXTWM2OD1{Mz6yNVI5KM7:TR?= MULTRW5ITVJ?
GAMG NGXZbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjvN5JLUUN3ME2yN{4zOzZ5IN88US=> NYKwVlFiW0GQR1XS
SW1573 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ|Lke0NVUh|ryP MkL0V2FPT0WU
MHH-NB-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonHTWM2OD1{ND6wNVk1KM7:TR?= Mkj5V2FPT0WU
TK10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXUNmpyUUN3ME2yOE42ODF|IN88US=> M2\ObHNCVkeHUh?=
LB373-MEL-D MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHaTWM2OD1{ND62NFY1KM7:TR?= M1PZfnNCVkeHUh?=
KALS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPC[oNzUUN3ME2yOE44OzJ5IN88US=> MkPPV2FPT0WU
HUTU-80 M3PKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknNTWM2OD1{NT64NFMzKM7:TR?= M4r5bXNCVkeHUh?=
HuP-T3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXXNnFjUUN3ME2yOk4yPjd2IN88US=> NV7Ieol1W0GQR1XS
OE19 NYf0PHlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;1VGlEPTB;Mk[uNlE2OyEQvF2= NV7MVIlFW0GQR1XS
J82 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3STWM2OD1{Nj6yOFcyKM7:TR?= NVfmPVhZW0GQR1XS
DU-4475 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ4LkO4NVkh|ryP NXLJdI5bW0GQR1XS
DMS-53 M1XtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGeycWRKSzVyPUK2MlUyOzhizszN M2PsNXNCVkeHUh?=
COLO-741 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ4LkizOFQh|ryP NIDQXlJUSU6JRWK=
SW48 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLDTWM2OD1{Nj64PFIh|ryP Mmf0V2FPT0WU
IGR-1 M37tVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ4LkmzN|Qh|ryP NFjDTFVUSU6JRWK=
639-V NIrvbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfLNWdKSzVyPUK3MlAzPDVizszN NYXXPXUyW0GQR1XS
LK-2 NEL6[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTETWM2OD1{Nz60NVQyKM7:TR?= M2ezVHNCVkeHUh?=
NCI-H2347 M{nodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfhWGpzUUN3ME2yO{46Pjl7IN88US=> MmXTV2FPT0WU
NCI-H2228 M1vsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLoTWM2OD1{OD6wPVA2KM7:TR?= NE\r[JdUSU6JRWK=
LS-123 M2Xpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnYTWM2OD1{OD6xNlYzKM7:TR?= MUHTRW5ITVJ?
U031 M{PZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETLSWNKSzVyPUK4MlI2OiEQvF2= NFH1RWNUSU6JRWK=
NCI-H1792 M1u5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS5cHJlUUN3ME2yPE41PzJzIN88US=> MYLTRW5ITVJ?
NCI-H2087 M1rTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW3T3hYUUN3ME2yPE44PTV{IN88US=> Mo[5V2FPT0WU
NCI-H2342 M1HtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33lU2lEPTB;MkmuOVIxQCEQvF2= M2jDOnNCVkeHUh?=
SW626 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\hU4hpUUN3ME2yPU44PTZizszN MYPTRW5ITVJ?
LB2518-MEL NVL5SZZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\jfJhXUUN3ME2yPU45OTVizszN NVnDbmxQW0GQR1XS
RXF393 NIPjVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPlNXRKSzVyPUOwMlA6PTJizszN MY\TRW5ITVJ?
LC4-1 NIi2UZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrpTWM2OD1|MD6zNFkzKM7:TR?= M{TxS3NCVkeHUh?=
NCI-H1694 MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLGOnI5UUN3ME2zNE43PjJ2IN88US=> NGrocJRUSU6JRWK=
K5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\TTWM2OD1|MD65O|AzKM7:TR?= NFzLVmJUSU6JRWK=
HDLM-2 MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jMR2lEPTB;M{CuPVczPSEQvF2= M4nvenNCVkeHUh?=
BCPAP NH7FZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILrNHJKSzVyPUOxMlg{PzlizszN MYrTRW5ITVJ?
BC-3 NV2zSG5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjvTWM2OD1|Mj6xOFA{KM7:TR?= MlHwV2FPT0WU
LB996-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLHTWM2OD1|Mj6yN|U5KM7:TR?= NFuyTJhUSU6JRWK=
NCI-H2009 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXMTWM2OD1|Mj60PVgyKM7:TR?= NVzkNGtbW0GQR1XS
HTC-C3 Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLqdVNKSzVyPUOzMlc2OTlizszN M3foW3NCVkeHUh?=
LAMA-84 NITiTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz2TWM2OD1|ND60OFA4KM7:TR?= M{PZfXNCVkeHUh?=
CCRF-CEM MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3yTWM2OD1|ND61O|E2KM7:TR?= MmXkV2FPT0WU
AN3-CA M{DFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7pdo5wUUN3ME2zOU4xPTZ6IN88US=> MoH3V2FPT0WU
NCI-H1734 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DlUGlEPTB;M{WuNlU3OSEQvF2= NFvOVIFUSU6JRWK=
Ca-Ski NYPjZ4s6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr4fHJKSzVyPUO1MlQyODFizszN NHPl[FJUSU6JRWK=
U-266 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3QPXdKSzVyPUO1MlYyOTRizszN MlPIV2FPT0WU
SBC-5 M1\vOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjLe3hKSzVyPUO1Mlc4QDFizszN NWH4OWkzW0GQR1XS
GT3TKB NGfGWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TROmlEPTB;M{euNVE2KM7:TR?= M1[xfHNCVkeHUh?=
MDA-MB-175-VII NWmwTVlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWwTWM2OD1|Nz6yNlQ5KM7:TR?= NWLBd4ZWW0GQR1XS
PFSK-1 MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTN5LkK0N|Uh|ryP NXLM[lF2W0GQR1XS
IMR-5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDEcWlUUUN3ME2zO{4zPDh5IN88US=> NW\hcWZNW0GQR1XS
Daudi NVixXFU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn1[JNzUUN3ME2zO{4{PTl5IN88US=> NG\Ge3lUSU6JRWK=
A498 MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TkWmlEPTB;M{euO|IyQCEQvF2= M{DET3NCVkeHUh?=
SCC-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm4VVFnUUN3ME2zO{44QDR|IN88US=> M33vOnNCVkeHUh?=
COLO-680N MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fBd2lEPTB;M{iuNlg5PSEQvF2= NUPifFc1W0GQR1XS
SK-MES-1 NXnT[Go1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvjTWM2OD1|OD6zNlE2KM7:TR?= NFnnWWVUSU6JRWK=
SR MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LIWGlEPTB;M{iuOVQ6PSEQvF2= MkPpV2FPT0WU
LNCaP-Clone-FGC M2jrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\qO2NKSzVyPUO4MlU3OzdizszN NGj0bmdUSU6JRWK=
SK-HEP-1 NVTjdJpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTN6Lke4NlIh|ryP MnnLV2FPT0WU
BPH-1 M{Pte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\5b2lEPTB;M{iuPFMzQSEQvF2= NV;kb4lZW0GQR1XS
NCI-H1755 NGH6PXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYruU2dXUUN3ME2zPU42QDF5IN88US=> M1;ycHNCVkeHUh?=
LXF-289 NV\ke|VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN7LkiwPFQh|ryP NVvSdGpqW0GQR1XS
SW1088 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHOSpRDUUN3ME20NE4zOTB5IN88US=> NIjyW4xUSU6JRWK=
MOLT-4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HBXmlEPTB;NECuNlkxOSEQvF2= MkjsV2FPT0WU
AsPC-1 M3zUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXGTWM2OD12MD60OVg{KM7:TR?= NIjGSWVUSU6JRWK=
HOP-62 M4TMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRyLk[1Olgh|ryP MmHsV2FPT0WU
A172 NVPmT5VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TkTGlEPTB;NECuPFUyOSEQvF2= M3HTeHNCVkeHUh?=
SN12C MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLnTWM2OD12MD65N|g2KM7:TR?= M3rDXXNCVkeHUh?=
MDA-MB-231 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\pOGlEPTB;NECuPVg6QCEQvF2= NYfVdFQ{W0GQR1XS
RPMI-2650 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTRzLkG1PVMh|ryP NEW1OWRUSU6JRWK=
KYSE-140 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\sRlZNUUN3ME20NU45OTJ|IN88US=> MWTTRW5ITVJ?
KINGS-1 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR{LkS2PVch|ryP MWTTRW5ITVJ?
HSC-3 M1j1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\JdmJKSzVyPUSyMlY3PjFizszN NHf0b3RUSU6JRWK=
PC-14 NF3y[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[zT2lEPTB;NEOuNVg5OiEQvF2= M{fsWXNCVkeHUh?=
COR-L105 M1fC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\KeJpKSzVyPUSzMlY2ODJizszN M{P5SnNCVkeHUh?=
BE-13 M2LPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXMWFJOUUN3ME20OE4zOzdzIN88US=> MkjjV2FPT0WU
NCI-H661 M1fpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7HTWM2OD12ND6yPVU5KM7:TR?= NE\HVZJUSU6JRWK=
IST-MEL1 NHjoPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDQVlU3UUN3ME20OE4{PTl7IN88US=> NFrpb|dUSU6JRWK=
HCC1806 NVrq[ZNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTR2LkW4O|Mh|ryP NHnPcJVUSU6JRWK=
COLO-800 M{P5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDmTWM2OD12ND64OFU{KM7:TR?= MlzuV2FPT0WU
IST-SL2 NWrk[ZZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXroXGN1UUN3ME20OU4yOjR5IN88US=> NWHxe213W0GQR1XS
8305C M{TPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEWxWFFKSzVyPUS1MlMxQSEQvF2= MlrsV2FPT0WU
UACC-62 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\HT2lEPTB;NE[uNlg4PSEQvF2= M3HLfnNCVkeHUh?=
COR-L23 M1fwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3qTWM2OD12Nz6xPVkh|ryP NGnNSFhUSU6JRWK=
EFE-184 M3LrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DqNmlEPTB;NEeuN|g5KM7:TR?= MlKwV2FPT0WU
DMS-114 M2TqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ywSmlEPTB;NEeuOFE1QSEQvF2= NXLkPI1FW0GQR1XS
KYSE-520 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWizZYc4UUN3ME20PE42OzF3IN88US=> NGDYemNUSU6JRWK=
SNG-M NVLuXXZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILSc2lKSzVyPUS5MlQ{PCEQvF2= NHLVZZpUSU6JRWK=
A2058 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPxTWM2OD12OT60PFg2KM7:TR?= MkDuV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
細胞試験: [1]
+ 展開
  • 細胞株: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • 濃度: 0.02-0.8 μM
  • 反応時間: 3 days
  • 実験の流れ: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • 製剤: 25 mM tartaric acid
  • 投薬量: 25 mg / kg and 75 mg / kg
  • 投与方法: Orally administrated at once-daily oral dose for 14 days
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
混合させたのち直ちに使用することを推奨します。
30mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 421.49
化学式

C26H23N5O

CAS No. 867160-71-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1Rシグナル伝達経路

IGF-1R Inhibitors with Unique Features

相関IGF-1R製品

Tags: Linsitinib (OSI-906)を買う | Linsitinib (OSI-906) ic50 | Linsitinib (OSI-906)供給者 | Linsitinib (OSI-906)を購入する | Linsitinib (OSI-906)費用 | Linsitinib (OSI-906)生産者 | オーダーLinsitinib (OSI-906) | Linsitinib (OSI-906)化学構造 | Linsitinib (OSI-906)分子量 | Linsitinib (OSI-906)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID